Alvilde M Ossum1,2, Øyvind Palm3, Aida Kapic Lunder2,4, Milada Cvancarova1,5, Hasan Banitalebi4, Anne Negård4, Ole Høie6, Magne Henriksen7, Bjørn A Moum1,2, Marte Lie Høivik1. 1. Department of Gastroenterology, Oslo University Hospital, Oslo, Norway. 2. Faculty of Medicine, University of Oslo, Oslo, Norway. 3. Department of Rheumatology, Oslo University Hospital, Oslo, Norway. 4. Department of Diagnostic Imaging, Akershus University Hospital, Oslo, Norway. 5. Faculty of Public Health, Oslo and Akershus University College, Oslo, Norway. 6. Sørlandet Hospital, Department of Internal Medicine, Arendal, Norway. 7. Østfold Hospital Trust, Gastroenterology, Grålum, Norway.
Abstract
BACKGROUND: Patients with inflammatory bowel disease [IBD] often suffer from rheumatic manifestations, including inflammatory back disorders. The prevalence of these disorders late in the course of IBD is poorly investigated. The aim of this study was to estimate the prevalence of inflammatory back disorders in patients with IBD 20 years after diagnosis, and to investigate possible associations with IBD severity, HLA-B27, and the NOD2 genotype. METHODS: A population-based cohort [the IBSEN study] was followed prospectively for 20 years. Information covering IBD activity and rheumatic diseases was collected at the regular follow-ups. HLA-B27 and NOD2 were analysed as present or absent. RESULTS: At 20 years, 599 members of the original cohort were alive, of whom 470 [78.5%] were investigated [314 ulcerative colitis and 156 Crohn's disease patients]. Ankylosing spondylitis was diagnosed in 21 patients [4.5%], axial spondyloarthritis was diagnosed in 36 patients [7.7%], and inflammatory back pain was diagnosed in 54 patients [11.5%]. Chronic back pain [back pain > 3 months] was present in 220 patients [46.8%]. HLA-B27 was associated with ankylosing spondylitis, axial spondyloarthritis, and inflammatory back pain, whereas no significant association was found for NOD2. A more chronic IBD course was associated with axial spondyloarthritis. CONCLUSIONS: Our data revealed a high prevalence of ankylosing spondylitis, axial spondyloarthritis, and inflammatory back pain 20 years after the IBD diagnosis. HLA-B27 but not NOD-2 was a predisposing factor for the inflammatory back disorders in IBD patients. Axial spondyloarthritis was associated with a more chronic active IBD disease course.
BACKGROUND: Patients with inflammatory bowel disease [IBD] often suffer from rheumatic manifestations, including inflammatory back disorders. The prevalence of these disorders late in the course of IBD is poorly investigated. The aim of this study was to estimate the prevalence of inflammatory back disorders in patients with IBD 20 years after diagnosis, and to investigate possible associations with IBD severity, HLA-B27, and the NOD2 genotype. METHODS: A population-based cohort [the IBSEN study] was followed prospectively for 20 years. Information covering IBD activity and rheumatic diseases was collected at the regular follow-ups. HLA-B27 and NOD2 were analysed as present or absent. RESULTS: At 20 years, 599 members of the original cohort were alive, of whom 470 [78.5%] were investigated [314 ulcerative colitis and 156 Crohn's disease patients]. Ankylosing spondylitis was diagnosed in 21 patients [4.5%], axial spondyloarthritis was diagnosed in 36 patients [7.7%], and inflammatory back pain was diagnosed in 54 patients [11.5%]. Chronic back pain [back pain > 3 months] was present in 220 patients [46.8%]. HLA-B27 was associated with ankylosing spondylitis, axial spondyloarthritis, and inflammatory back pain, whereas no significant association was found for NOD2. A more chronic IBD course was associated with axial spondyloarthritis. CONCLUSIONS: Our data revealed a high prevalence of ankylosing spondylitis, axial spondyloarthritis, and inflammatory back pain 20 years after the IBD diagnosis. HLA-B27 but not NOD-2 was a predisposing factor for the inflammatory back disorders in IBD patients. Axial spondyloarthritis was associated with a more chronic active IBD disease course.
Authors: Eric Gracey; Lars Vereecke; Dermot McGovern; Mareike Fröhling; Georg Schett; Silvio Danese; Martine De Vos; Filip Van den Bosch; Dirk Elewaut Journal: Nat Rev Rheumatol Date: 2020-07-13 Impact factor: 20.543
Authors: Lars E Bartels; Alma B Pedersen; Nickolaj R Kristensen; Hendrik Vilstrup; Kristian Stengaard-Pedersen; Jens F Dahlerup Journal: Rheumatol Int Date: 2019-12-04 Impact factor: 2.631
Authors: Charles N Bernstein; Eric I Benchimol; Alain Bitton; Sanjay K Murthy; Geoffrey C Nguyen; Kate Lee; Jane Cooke-Lauder; Gilaad G Kaplan Journal: J Can Assoc Gastroenterol Date: 2018-11-02
Authors: Anand Kumar; Dana Lukin; Robert Battat; Monica Schwartzman; Lisa A Mandl; Ellen Scherl; Randy S Longman Journal: J Gastroenterol Date: 2020-05-04 Impact factor: 7.527